Congenital Heart Diseases Market - Global Outlook and Forecast 2022-2028

March 2022 | 66 pages | ID: C2EE428FA459EN
Market Monitor Global

Abstracts

Congenital diseases are disorders in a newborn due to certain genetic factors (and sometimes in association with the environment) that often results in malformations or underdeveloped organs. Congenital Heart Diseases (CHD) results in malformed or undeveloped heart that presents in a newborn with breathing and circulation disorders. According to Lancet medical journal, CHD caused death of 0.22 million individuals and newborns globally in the year 2010. CHD was earlier erroneously associated with premature births, the association has no direct correlation with all forms of CHD and is mainly one of the many factors that can cause it. The genetic factors causing CHD consist of chromosomal errors in fertilization and the following meiotic division, these include: large chromosomal defects in trisomal chromosomes; small chromosomal defects like microdeletion of long/short arm of chromosome and random/environmentally induced mutation of heart muscle cell proteins, or associated proteins etc. The environmental factors like rubella infections, thalidomide drugs, metals (lithium, lead, mercury, etc), chronic illness in the mother (systemic lupus, diabetes, phenylketonuria, etc). Embryological changes, hormonal changes in the mother and certain birth deficiencies can also cause CHD and other birth defects in children. Besides these, according to some medical research reports, maternal obesity increased the chances of CHD in newborns; obesity was shown to increase the risk of previously hidden genetic traits of CHD in the new born children of such obese mothers.

This report contains market size and forecasts of Congenital Heart Diseases in Global, including the following market information:

Global Congenital Heart Diseases Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Congenital Heart Diseases market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Hypoplasia Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Congenital Heart Diseases include Pfizer, Abbott Laboratories, Eli Lilly and Ranbaxy Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Congenital Heart Diseases companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Congenital Heart Diseases Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Congenital Heart Diseases Market Segment Percentages, by Type, 2021 (%)

• Hypoplasia
• Obstructive
• Septal Defects

Global Congenital Heart Diseases Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Congenital Heart Diseases Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Ambulatory Surgical Centers
• Diagnostic Centers
• Others

Global Congenital Heart Diseases Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Congenital Heart Diseases Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Congenital Heart Diseases revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Congenital Heart Diseases revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer
• Abbott Laboratories
• Eli Lilly
• Ranbaxy Pharmaceutical

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Congenital Heart Diseases Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Congenital Heart Diseases Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CONGENITAL HEART DISEASES OVERALL MARKET SIZE

2.1 Global Congenital Heart Diseases Market Size: 2021 VS 2028
2.2 Global Congenital Heart Diseases Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Congenital Heart Diseases Players in Global Market
3.2 Top Global Congenital Heart Diseases Companies Ranked by Revenue
3.3 Global Congenital Heart Diseases Revenue by Companies
3.4 Top 3 and Top 5 Congenital Heart Diseases Companies in Global Market, by Revenue in 2021
3.5 Global Companies Congenital Heart Diseases Product Type
3.6 Tier 1, Tier 2 and Tier 3 Congenital Heart Diseases Players in Global Market
  3.6.1 List of Global Tier 1 Congenital Heart Diseases Companies
  3.6.2 List of Global Tier 2 and Tier 3 Congenital Heart Diseases Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Congenital Heart Diseases Market Size Markets, 2021 & 2028
  4.1.2 Hypoplasia
  4.1.3 Obstructive
  4.1.4 Septal Defects
4.2 By Type - Global Congenital Heart Diseases Revenue & Forecasts
  4.2.1 By Type - Global Congenital Heart Diseases Revenue, 2017-2022
  4.2.2 By Type - Global Congenital Heart Diseases Revenue, 2023-2028
  4.2.3 By Type - Global Congenital Heart Diseases Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Congenital Heart Diseases Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Ambulatory Surgical Centers
  5.1.4 Diagnostic Centers
  5.1.5 Others
5.2 By Application - Global Congenital Heart Diseases Revenue & Forecasts
  5.2.1 By Application - Global Congenital Heart Diseases Revenue, 2017-2022
  5.2.2 By Application - Global Congenital Heart Diseases Revenue, 2023-2028
  5.2.3 By Application - Global Congenital Heart Diseases Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Congenital Heart Diseases Market Size, 2021 & 2028
6.2 By Region - Global Congenital Heart Diseases Revenue & Forecasts
  6.2.1 By Region - Global Congenital Heart Diseases Revenue, 2017-2022
  6.2.2 By Region - Global Congenital Heart Diseases Revenue, 2023-2028
  6.2.3 By Region - Global Congenital Heart Diseases Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Congenital Heart Diseases Revenue, 2017-2028
  6.3.2 US Congenital Heart Diseases Market Size, 2017-2028
  6.3.3 Canada Congenital Heart Diseases Market Size, 2017-2028
  6.3.4 Mexico Congenital Heart Diseases Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Congenital Heart Diseases Revenue, 2017-2028
  6.4.2 Germany Congenital Heart Diseases Market Size, 2017-2028
  6.4.3 France Congenital Heart Diseases Market Size, 2017-2028
  6.4.4 U.K. Congenital Heart Diseases Market Size, 2017-2028
  6.4.5 Italy Congenital Heart Diseases Market Size, 2017-2028
  6.4.6 Russia Congenital Heart Diseases Market Size, 2017-2028
  6.4.7 Nordic Countries Congenital Heart Diseases Market Size, 2017-2028
  6.4.8 Benelux Congenital Heart Diseases Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Congenital Heart Diseases Revenue, 2017-2028
  6.5.2 China Congenital Heart Diseases Market Size, 2017-2028
  6.5.3 Japan Congenital Heart Diseases Market Size, 2017-2028
  6.5.4 South Korea Congenital Heart Diseases Market Size, 2017-2028
  6.5.5 Southeast Asia Congenital Heart Diseases Market Size, 2017-2028
  6.5.6 India Congenital Heart Diseases Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Congenital Heart Diseases Revenue, 2017-2028
  6.6.2 Brazil Congenital Heart Diseases Market Size, 2017-2028
  6.6.3 Argentina Congenital Heart Diseases Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Congenital Heart Diseases Revenue, 2017-2028
  6.7.2 Turkey Congenital Heart Diseases Market Size, 2017-2028
  6.7.3 Israel Congenital Heart Diseases Market Size, 2017-2028
  6.7.4 Saudi Arabia Congenital Heart Diseases Market Size, 2017-2028
  6.7.5 UAE Congenital Heart Diseases Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer
  7.1.1 Pfizer Corporate Summary
  7.1.2 Pfizer Business Overview
  7.1.3 Pfizer Congenital Heart Diseases Major Product Offerings
  7.1.4 Pfizer Congenital Heart Diseases Revenue in Global Market (2017-2022)
  7.1.5 Pfizer Key News
7.2 Abbott Laboratories
  7.2.1 Abbott Laboratories Corporate Summary
  7.2.2 Abbott Laboratories Business Overview
  7.2.3 Abbott Laboratories Congenital Heart Diseases Major Product Offerings
  7.2.4 Abbott Laboratories Congenital Heart Diseases Revenue in Global Market (2017-2022)
  7.2.5 Abbott Laboratories Key News
7.3 Eli Lilly
  7.3.1 Eli Lilly Corporate Summary
  7.3.2 Eli Lilly Business Overview
  7.3.3 Eli Lilly Congenital Heart Diseases Major Product Offerings
  7.3.4 Eli Lilly Congenital Heart Diseases Revenue in Global Market (2017-2022)
  7.3.5 Eli Lilly Key News
7.4 Ranbaxy Pharmaceutical
  7.4.1 Ranbaxy Pharmaceutical Corporate Summary
  7.4.2 Ranbaxy Pharmaceutical Business Overview
  7.4.3 Ranbaxy Pharmaceutical Congenital Heart Diseases Major Product Offerings
  7.4.4 Ranbaxy Pharmaceutical Congenital Heart Diseases Revenue in Global Market (2017-2022)
  7.4.5 Ranbaxy Pharmaceutical Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Congenital Heart Diseases Market Opportunities & Trends in Global Market
Table 2. Congenital Heart Diseases Market Drivers in Global Market
Table 3. Congenital Heart Diseases Market Restraints in Global Market
Table 4. Key Players of Congenital Heart Diseases in Global Market
Table 5. Top Congenital Heart Diseases Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Congenital Heart Diseases Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Congenital Heart Diseases Revenue Share by Companies, 2017-2022
Table 8. Global Companies Congenital Heart Diseases Product Type
Table 9. List of Global Tier 1 Congenital Heart Diseases Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Congenital Heart Diseases Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Congenital Heart Diseases Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Congenital Heart Diseases Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Congenital Heart Diseases Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Congenital Heart Diseases Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Congenital Heart Diseases Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Congenital Heart Diseases Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Congenital Heart Diseases Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Congenital Heart Diseases Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Congenital Heart Diseases Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Congenital Heart Diseases Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Congenital Heart Diseases Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Congenital Heart Diseases Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Congenital Heart Diseases Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Congenital Heart Diseases Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Congenital Heart Diseases Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Congenital Heart Diseases Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Congenital Heart Diseases Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Congenital Heart Diseases Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Congenital Heart Diseases Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Congenital Heart Diseases Product Offerings
Table 32. Pfizer Congenital Heart Diseases Revenue (US$, Mn), (2017-2022)
Table 33. Abbott Laboratories Corporate Summary
Table 34. Abbott Laboratories Congenital Heart Diseases Product Offerings
Table 35. Abbott Laboratories Congenital Heart Diseases Revenue (US$, Mn), (2017-2022)
Table 36. Eli Lilly Corporate Summary
Table 37. Eli Lilly Congenital Heart Diseases Product Offerings
Table 38. Eli Lilly Congenital Heart Diseases Revenue (US$, Mn), (2017-2022)
Table 39. Ranbaxy Pharmaceutical Corporate Summary
Table 40. Ranbaxy Pharmaceutical Congenital Heart Diseases Product Offerings
Table 41. Ranbaxy Pharmaceutical Congenital Heart Diseases Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Congenital Heart Diseases Segment by Type in 2021
Figure 2. Congenital Heart Diseases Segment by Application in 2021
Figure 3. Global Congenital Heart Diseases Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Congenital Heart Diseases Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Congenital Heart Diseases Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Congenital Heart Diseases Revenue in 2021
Figure 8. By Type - Global Congenital Heart Diseases Revenue Market Share, 2017-2028
Figure 9. By Application - Global Congenital Heart Diseases Revenue Market Share, 2017-2028
Figure 10. By Region - Global Congenital Heart Diseases Revenue Market Share, 2017-2028
Figure 11. By Country - North America Congenital Heart Diseases Revenue Market Share, 2017-2028
Figure 12. US Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Congenital Heart Diseases Revenue Market Share, 2017-2028
Figure 16. Germany Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 17. France Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Congenital Heart Diseases Revenue Market Share, 2017-2028
Figure 24. China Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 28. India Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Congenital Heart Diseases Revenue Market Share, 2017-2028
Figure 30. Brazil Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Congenital Heart Diseases Revenue Market Share, 2017-2028
Figure 33. Turkey Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Congenital Heart Diseases Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Congenital Heart Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Abbott Laboratories Congenital Heart Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Eli Lilly Congenital Heart Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Ranbaxy Pharmaceutical Congenital Heart Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)